Operating Units & Divisions
Board of Directors
Cell Systems Informatics
Neurospora & Agaricus Platforms
Endometrial Regenerative Cells
Porcine Research Models
Exclusive Channel Collaborations
Intrexon Institute for Biomolecular Research
At Intrexon we are committed to building…
A Better World Through Better DNA™
Whether engineering novel therapies in health, delivering unique solutions to address global energy demand, enabling unparalleled productivity advancements in food, or developing innovative applications in the consumer and environment sectors, we are working diligently today to create a better tomorrow.
Engineering novel solutions in
to achieve improved outcomes
Building a sustainable path to produce healthy, affordable
Utilizing a proprietary bioconversion platform for efficient
Developing innovative solutions for the
Designing bio based
Engineering Microbes for Commercial Products: From Fuels & Chemicals to APIs
Precise Gene Expression:
Proprietary RheoSwitch Technology Platform
Industry Leading Reproductive Technologies
IN THE NEWS
Intrexon Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for RheoSwitch® Controlled IL-12 Cancer Therapies Using T cell Receptors (TCR) Derived from Peripheral Blood
4/1/2015 1:05:50 PM
GERMANTOWN, Md., April 1, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that Intrexon has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System® (RTS®) platform for the treatment of solid tumor malignancies. The principal goal of the CRADA is to develop and evaluate improved adoptive cell transfer-based immunotherapies (ACT) using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes (PBL) possessing naturally occur...
ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
3/30/2015 5:14:00 AM
BOSTON and GERMANTOWN, Md., March 30, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreeme...
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
3/30/2015 5:02:22 AM
- Chimeric Antigen Receptor T-cell (CAR-T) therapy enhances Merck Serono's R&D technology portfolio in immuno-oncology - Collaboration and license agreement will focus on developing a next generation CAR-T platform to generate several drug candidates GERMANTOWN, Md., March 30, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven stra...
Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results
3/2/2015 2:05:46 PM
Quarterly Net Income of $18.8M or $0.19/share on 335% Revenue Growth FY2014 Adjusted EBITDA Positive, Achieving Key Management Goal GERMANTOWN, Md., March 2, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its fourth quarter and full year results for 2014. Business Highlights and Recent Developments: Acquired ActoGeniX, a European clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics and other innovative products. Its proprietary TopAct™ platform enables the molecular engineering of food-grade microbes (Lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ ex...